Celldex Therapeutics Profit Margin 2010-2022 | CLDX
Current and historical gross margin, operating margin and net profit margin for Celldex Therapeutics (CLDX) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Celldex Therapeutics net profit margin as of December 31, 2022 is -4765.59%.
| Celldex Therapeutics Annual Profit Margins |
| Celldex Therapeutics Quarterly Profit Margins |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.642B |
$0.002B |
|
CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
|
